NZ770323A - Addition salt of s1p1 receptor agonist and crystal form thereof, and pharmaceutical composition - Google Patents
Addition salt of s1p1 receptor agonist and crystal form thereof, and pharmaceutical compositionInfo
- Publication number
- NZ770323A NZ770323A NZ770323A NZ77032318A NZ770323A NZ 770323 A NZ770323 A NZ 770323A NZ 770323 A NZ770323 A NZ 770323A NZ 77032318 A NZ77032318 A NZ 77032318A NZ 770323 A NZ770323 A NZ 770323A
- Authority
- NZ
- New Zealand
- Prior art keywords
- crystal form
- pharmaceutical composition
- addition salt
- receptor agonist
- salt form
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2018/085617 WO2019210511A1 (zh) | 2018-05-04 | 2018-05-04 | 一种s1p1受体激动剂的加成盐及其晶型和药物组合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ770323A true NZ770323A (en) | 2025-12-19 |
Family
ID=68387039
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ770323A NZ770323A (en) | 2018-05-04 | 2018-05-04 | Addition salt of s1p1 receptor agonist and crystal form thereof, and pharmaceutical composition |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US11512078B2 (https=) |
| EP (2) | EP4353719B1 (https=) |
| JP (3) | JP7275253B2 (https=) |
| KR (2) | KR20240094023A (https=) |
| AU (1) | AU2018421487B2 (https=) |
| CA (1) | CA3099196A1 (https=) |
| ES (1) | ES2978392T3 (https=) |
| IL (3) | IL312512B2 (https=) |
| MX (1) | MX2020011665A (https=) |
| NZ (1) | NZ770323A (https=) |
| SG (1) | SG11202010969UA (https=) |
| WO (1) | WO2019210511A1 (https=) |
| ZA (1) | ZA202007347B (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ770323A (en) * | 2018-05-04 | 2025-12-19 | Suzhou Connect Biopharmaceuticals Ltd | Addition salt of s1p1 receptor agonist and crystal form thereof, and pharmaceutical composition |
| WO2022099155A1 (en) * | 2020-11-09 | 2022-05-12 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the s1p1 receptor |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005533058A (ja) * | 2002-06-17 | 2005-11-04 | メルク エンド カムパニー インコーポレーテッド | Ｅｄｇ受容体アゴニストとしての１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）アゼチジン−３−カルボキシラートおよび１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）ピロリジン−３−カルボキシラート |
| WO2004035538A1 (en) | 2002-10-15 | 2004-04-29 | Merck & Co., Inc. | Process for making azetidine-3-carboxylic acid |
| CN103450171B (zh) | 2013-09-22 | 2015-07-08 | 苏州康乃德生物医药有限公司 | 一种免疫调节化合物、其用途和包含其的药物组合物 |
| CN105315266B (zh) * | 2014-08-01 | 2019-10-01 | 苏州康乃德生物医药有限公司 | 1-{2-氟-4-[5-(4-异丁基苯基)-1,2,4-噁二唑-3-基]-苄基}-3-吖丁啶羧酸的晶型 |
| CN105348276B (zh) | 2014-08-22 | 2020-05-26 | 苏州康乃德生物医药有限公司 | 1-{2-氟-4-[5-(4-异丁基苯基)-1,2,4-噁二唑-3-基]-苄基}-3-吖丁啶羧酸的合成方法 |
| CN112778290B (zh) | 2017-01-11 | 2022-12-06 | 苏州康乃德生物医药有限公司 | 一种s1p1受体激动剂的加成盐及其晶型和药物组合物 |
| NZ770323A (en) * | 2018-05-04 | 2025-12-19 | Suzhou Connect Biopharmaceuticals Ltd | Addition salt of s1p1 receptor agonist and crystal form thereof, and pharmaceutical composition |
-
2018
- 2018-05-04 NZ NZ770323A patent/NZ770323A/en unknown
- 2018-05-04 ES ES18917186T patent/ES2978392T3/es active Active
- 2018-05-04 AU AU2018421487A patent/AU2018421487B2/en active Active
- 2018-05-04 CA CA3099196A patent/CA3099196A1/en active Pending
- 2018-05-04 WO PCT/CN2018/085617 patent/WO2019210511A1/zh not_active Ceased
- 2018-05-04 JP JP2021510499A patent/JP7275253B2/ja active Active
- 2018-05-04 KR KR1020247018420A patent/KR20240094023A/ko active Pending
- 2018-05-04 IL IL312512A patent/IL312512B2/en unknown
- 2018-05-04 SG SG11202010969UA patent/SG11202010969UA/en unknown
- 2018-05-04 EP EP24155906.1A patent/EP4353719B1/en active Active
- 2018-05-04 IL IL278464A patent/IL278464B2/en unknown
- 2018-05-04 EP EP18917186.1A patent/EP3792258B1/en active Active
- 2018-05-04 KR KR1020207034174A patent/KR102672632B1/ko active Active
- 2018-05-04 MX MX2020011665A patent/MX2020011665A/es unknown
- 2018-05-04 US US17/052,160 patent/US11512078B2/en active Active
-
2020
- 2020-11-25 ZA ZA2020/07347A patent/ZA202007347B/en unknown
-
2022
- 2022-10-06 US US17/961,270 patent/US12202822B2/en active Active
-
2023
- 2023-02-17 JP JP2023023091A patent/JP7651198B2/ja active Active
-
2024
- 2024-12-11 US US18/977,539 patent/US20250320200A1/en active Pending
-
2025
- 2025-03-06 JP JP2025035420A patent/JP2025074350A/ja active Pending
- 2025-09-29 IL IL323665A patent/IL323665A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202103587B (en) | Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as atr kinase inhibitors | |
| ZA202109587B (en) | Glucagon-like peptide 1 receptor agonists | |
| EP4342540A3 (en) | Substituted heterocyclyl derivatives as cdk inhibitors | |
| EP4631944A3 (en) | Rimegepant for cgrp related disorders | |
| MX2018011813A (es) | Medicina obtenida mediante la combinacion de agonista fxr y arb. | |
| US20140228418A1 (en) | Combination therapy of hsp90 inhibitory compounds with mek inhibitors | |
| CY1109624T1 (el) | Υποκατεστημενα παραγωγα θειοφαινιου ως ανταγωνιστες υποδοχεα γλυκογονου, παρασκευη και θεραπευτικες χρησεις | |
| EA201691454A1 (ru) | Композиции придопидина модифицированного высвобождения | |
| CY1122170T1 (el) | Ορβεπιταντη για τη θεραπευτικη αγωγη χρονιου βηχα | |
| CY1109860T1 (el) | Παραγοντες υποδοχεα ισταμινης η3, παρασκευη και θεραπευτικες χρησεις | |
| EA201490014A1 (ru) | Модифицированное высвобождение 4-метил-3-[[4-(3-пиридинил)-2-пиримидинил]амино]-n-[5-(4-метил-1h-имидазол-1-ил)-3-(трифторметил)фенил]бензамида, солюбилизированного с использованием органических кислот | |
| EA201071094A1 (ru) | Тризамещенные 1,2,4-триазолы в качестве модуляторов никотиновых ацетилхолиновых рецепторов | |
| CL2011000806A1 (es) | Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular. | |
| PH12019500154A1 (en) | Formulation having improved ph-dependent drug-release characteristics, containing esomeprazole or pharmaceutically acceptable salt thereof | |
| PH12017502252B1 (en) | Stable pharmaceutical composition for oral administration | |
| WO2007092861A3 (en) | Inhibitors specific of presenilin-1 and their uses | |
| EA201990765A1 (ru) | Азаиндазольные соединения для применения при повреждениях сухожилий и/или связок | |
| MA42301B1 (fr) | Sel cristallin de fumarate de (s)-[3,4-difluoro-2-(2-fluoro-4-iodophénylamino)phényl][3-hydroxy-3-(pipéridin-2-yl)azétidin-1-yl]-méthanone | |
| PH12017501829A1 (en) | Pharmaceutical formulations | |
| WO2018027084A3 (en) | Combination of glucagon receptor antagonists and pi3k pathway inhibitors for the treatment of cancer | |
| NZ770323A (en) | Addition salt of s1p1 receptor agonist and crystal form thereof, and pharmaceutical composition | |
| MX2015017058A (es) | Combinaciones farmaceuticas de un inhibidor de pi3k y un agente de desestabilizacion de microtubulos. | |
| CY1124301T1 (el) | Ενωσεις ινδαζολης για χρηση σε κακωσεις του τενοντα ή/και των συνδεσμων | |
| DK1951659T3 (da) | Glucagonreceptorantagonister, fremstilling og terapeutisk anvendelse heraf | |
| MX2023002721A (es) | Sal de adicion de agonista de receptor s1p1 y forma cristalina de la misma, y composicion farmaceutica. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 MAY 2027 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS Effective date: 20260326 |